Skip to main content

Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash.

Publication ,  Journal Article
Huber, AM; Kim, S; Reed, AM; Carrasco, R; Feldman, BM; Hong, SD; Kahn, P; Rahimi, H; Robinson, AB; Vehe, RK; Weiss, JE; Spencer, C ...
Published in: J Rheumatol
January 2017

OBJECTIVE: Juvenile dermatomyositis (JDM) is the most common form of idiopathic inflammatory myopathy in children. While outcomes are generally thought to be good, persistence of skin rash is a common problem. The goal of this study was to describe the development of clinical treatment plans (CTP) for children with JDM characterized by persistent skin rash despite complete resolution of muscle involvement. METHODS: The Childhood Arthritis and Rheumatology Research Alliance, a North American consortium of pediatric rheumatologists and other healthcare providers, used a combination of Delphi surveys and nominal group consensus meetings to develop CTP that reflected consensus on typical treatments for patients with JDM with persistent skin rash. RESULTS: Consensus was reached on patient characteristics and outcome assessment. Patients should have previously received corticosteroids and methotrexate (MTX). Three consensus treatment plans were developed. Plan A added intravenous immunoglobulin (IVIG) if it was not already being used. Plan B added mycophenolate mofetil, while Plan C added cyclosporine. Continuation of previous treatments, including corticosteroids, MTX, and IVIG, was permitted in plans B and C. CONCLUSION: Three consensus CTP were developed for use in children with JDM and persistent skin rash despite complete resolution of muscle disease. These CTP reflect typical treatment approaches and are not to be considered treatment recommendations or standard of care. Using prospective data collection and statistical methods to account for nonrandom treatment assignment, it is expected that these CTP will be used to allow treatment comparisons, and ultimately determine the best treatment for these patients.

Duke Scholars

Published In

J Rheumatol

DOI

EISSN

1499-2752

Publication Date

January 2017

Volume

44

Issue

1

Start / End Page

110 / 116

Location

Canada

Related Subject Headings

  • Rheumatology
  • Methotrexate
  • Immunoglobulins, Intravenous
  • Humans
  • Exanthema
  • Drug Therapy, Combination
  • Dermatomyositis
  • Consensus
  • Child
  • Arthritis & Rheumatology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Huber, A. M., Kim, S., Reed, A. M., Carrasco, R., Feldman, B. M., Hong, S. D., … Juvenile Dermatomyositis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance, . (2017). Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash. J Rheumatol, 44(1), 110–116. https://doi.org/10.3899/jrheum.160688
Huber, Adam M., Susan Kim, Ann M. Reed, Ruy Carrasco, Brian M. Feldman, Sandy D. Hong, Philip Kahn, et al. “Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash.J Rheumatol 44, no. 1 (January 2017): 110–16. https://doi.org/10.3899/jrheum.160688.
Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, et al. Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash. J Rheumatol. 2017 Jan;44(1):110–6.
Huber, Adam M., et al. “Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash.J Rheumatol, vol. 44, no. 1, Jan. 2017, pp. 110–16. Pubmed, doi:10.3899/jrheum.160688.
Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, Kahn P, Rahimi H, Robinson AB, Vehe RK, Weiss JE, Spencer C, Juvenile Dermatomyositis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash. J Rheumatol. 2017 Jan;44(1):110–116.

Published In

J Rheumatol

DOI

EISSN

1499-2752

Publication Date

January 2017

Volume

44

Issue

1

Start / End Page

110 / 116

Location

Canada

Related Subject Headings

  • Rheumatology
  • Methotrexate
  • Immunoglobulins, Intravenous
  • Humans
  • Exanthema
  • Drug Therapy, Combination
  • Dermatomyositis
  • Consensus
  • Child
  • Arthritis & Rheumatology